炎症性肠病患者对抗肿瘤坏死因子-α单克隆抗体原发性失应答研究进展

Research Progress of Primary Non-response to Anti-TNF-α Monoclonal Antibody in Patients with Inflammatory Bowel Disease

摘要: 抗肿瘤坏死因子(TNF)-a单克隆抗体(单抗)现已广泛用于治疗激素依赖或难治性炎症性肠病(inflammatory bowel disease，IBD)患者，然而部分患者在治疗期间会出现原发性无应答。本综述就接受抗TNF-α单抗治疗的IBD患者发生原发性失应答的机制、预测标志物总结了目前相关研究进展，为实现IBD生物制剂治疗的精确化、个体化提供理论依据。

Abstract: Anti-tumor necrosis factor-a(anti-TNF-a) monoclonal antibodies are now widely used in patients with steroid-dependent or steroid-refractory inflammatory bowel disease(IBD). However, some patients will experience primary non-response(PNR) during treatment. This review summarized the current research progress on the mechanism and predictive markers of PNR in IBD patients treated with anti-TNF-α monoclonal antibodies, providing a theoretical basis for the realization of precise and individualized treatment of IBD biologics.